STOCK TITAN

Nkarta Inc - NKTX STOCK NEWS

Welcome to our dedicated news page for Nkarta (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nkarta's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nkarta's position in the market.

Rhea-AI Summary
Nkarta, Inc. (NKTX) will be participating in two investor conferences to discuss its engineered natural killer cell therapies. The events include the Needham Virtual Healthcare Conference on April 9 and the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences
-
Rhea-AI Summary
Nkarta, Inc. (NKTX) announces the pricing of a stock offering to raise approximately $240.1 million for research, development, and corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.6%
Tags
none
-
Rhea-AI Summary
Nkarta, Inc. (NKTX) reports financial results for Q4 and full year 2023, with cash position of $250.9 million. The company focuses on NKX019 in autoimmune diseases and deprioritizes NKX101. NKX019 shows promise in lupus nephritis and non-Hodgkin lymphoma, with positive clinical data. NKX101 in AML shows lower response rates, leading to deprioritization. Nkarta's cash runway is expected to fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.28%
Tags
Rhea-AI Summary
Nkarta, Inc. (NKTX) will be participating in three investor conferences to discuss its engineered natural killer cell therapies. The company will be featured in industry panels and fireside chats at the Cowen Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and H.C. Wainwright Annual Cell Therapy Virtual Conference. Investors can access webcasts of the events on Nkarta's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences
-
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX) presents follow-up data from Phase 1 clinical trial of NKX101 at 2023 ASH Annual Meeting, showing encouraging responses and early durability in patients with relapsed or refractory acute myeloid leukemia (r/r AML). No cases of adverse effects observed. Plans to provide an update in the first half of 2024 with preliminary safety and response data from additional patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX) expands its pipeline into autoimmune disease with the FDA clearance of IND for NKX019 in lupus nephritis. The company plans to initiate dosing in the clinical trial of NKX019 in patients with refractory lupus nephritis in the first half of 2024. Nkarta also reported financial results for the third quarter ended September 30, 2023, with cash and cash equivalents of $278.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX) will be participating in two investor conferences, the Stifel Healthcare Conference on November 14, 2023, and the Evercore ISI HealthCONx Conference on November 28, 2023. The company's participation will include fireside chats, and webcasts of the events will be available on Nkarta's website with a 90-day replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary
Lupus Therapeutics partners with Nkarta to develop NK cell therapy for lupus nephritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
112.16%
Tags
partnership
-
Rhea-AI Summary
Nkarta announces clearance of IND application for NKX019, an allogeneic CAR NK cell therapy candidate for lupus nephritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
112.16%
Tags
Rhea-AI Summary
Nkarta, Inc. to host conference call to discuss clinical program updates and cost measures
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
112.16%
Tags
conferences
Nkarta Inc

Nasdaq:NKTX

NKTX Rankings

NKTX Stock Data

615.52M
33.34M
5.16%
73.51%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About NKTX

nkarta therapeutics seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies. nkarta was founded on the proprietary, robust and well characterized natural killer (nk) cell expansion technology pioneered by dario campana. the company is focused on leveraging the natural potent power of nk cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. nkarta is combining its nk expansion platform technology with proprietary cell engineering technologies to build differentiated autologous and allogeneic cell therapy candidates for the treatment of cancer. founded in 2015, the company’s investors include sr one, nea and novo ventures. for more information, please visit the company’s website at www.nkartatx.com.